Premium
Use of a hormone‐sensitive (LNCaP) and a hormone‐resistant (LNCaP‐r) cell line in prostate cancer research
Author(s) -
Pousette Åke,
Carlström Kjell,
Henriksson Peter,
Grande Mirtha,
Stege Reinhard
Publication year - 1997
Publication title -
the prostate
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.295
H-Index - 123
eISSN - 1097-0045
pISSN - 0270-4137
DOI - 10.1002/(sici)1097-0045(19970515)31:3<198::aid-pros9>3.0.co;2-h
Subject(s) - lncap , prostate cancer , hormone , prostate , endocrinology , medicine , cancer research , oncology , cancer
BACKGROUND In order to develop a hormone‐resistant analog to the hormone sensitive cell‐line LNCaP, different methods were tried. METHODS After almost one year of continuous culture in RPMI‐1640, containing a low concentration of androgens, the hormone sensitive cell‐line LNCaP became hormone resistant and was named LNCaP‐r. RESULTS We used the LNCaP/LNCaP‐r model system in order to study methods for the parenteral treatment of prostate carcinoma with estrogens, to study the mechanism of action of estramustine, and to identify markers useful as predictive tests for prostate carcinoma. CONCLUSIONS A model system made up of the hormone sensitive prostate LNCaP cell‐line and the hormone resistant LNCaP‐r subline was developed and characterized. This system is, despite a number of limitations, easy to use as a first step to test different hypotheses that can be studied further in later clinical trials. Prostate 31:198–203, 1997. © 1997 Wiley‐Liss, Inc.